Patients who had undergone potentially curative surgery and completion of adjuvant therapy for stage II and III CRC were randomly assigned to receive rofecoxib (20 mg daily) or placebo. The primary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results